** Shares of drug developer Rezolute RZLT.O rise 4.7% to $3.78 premarket

** Co says it saw positive interim results in its late-stage trial testing the drug ersodetug in patients with tumor hyperinsulinism, a rare condition characterized by severely low blood sugar

** Co says six of eight participants have already met the main goal of achieving at least a 50% reduction from baseline in intravenous glucose requirements

** RZLT is midway through enrollment of the planned study sample size of 16 participants

** Up to last close, stock up 53% YTD